Clinical observation of Huoxue-Sanjie decoction combined with GEMOX chemotherapy regimen in the treatment of advanced pancreatic cancer for shireyudu syndrome / 国际中医中药杂志

ABSTRACT

Objective To evaluate the clinical effects ofHuoxue-Sanjie decoction combined with GEMOX chemotherapy regimen in the treatment of advanced pancreatic cancer with dampness-heat and stasis pattern.MethodsA total of 90 patients with advanced pancreatic cancer and TCM pattern of dampness-heat and stasis were enrolled from January 2012 to May 2014 in our hospital and randomly divided into control group (45 patients) and TCM group (45 patients). The control group was treated with GEMOX chemotherapy regimen used alone, while the TCM group was treated withHuoxue-Sanjie decoction assisted treatment based on control group. The clinical effects, quality improvement rate, immune function index and coagulation index before and after treatment and survival rate in 1 year after treatment and adverse events were compared between two groups.Results The total effective rate (73.33%vs. 66.67%,χ2=1.708,P=0.135) in TCM group was not significantly different from the control group. The survival rate in 1 year was (28.89%vs. 55.56%,χ2=10.406, P<0.01) in TCM group was significantly lower than that in control group. The adverse events (15.56% vs. 35.56%,χ2=8.728,P=0.002) in TCM group was significantly lower than that in control group. Compared with the control group, the CD3+ (65.20 ± 5.21 ratio/mlvs.62.94 ± 4.73 ratio/ml,t=2.106), CD4+ (36.86 ± 3.70 ratio/mlvs. 33.88 ± 3.04 ratio/ml,t=2.482), CD4+/CD8+(1.46 ± 0.30vs.1.36 ± 0.24,t=2.972) levels in TCM group increased significantly (P<0.05 orP<0.01). The PT (13.76 ± 1.70 svs. 14.73 ± 2.12 s,t=2.842), APTT (31.84 ± 2.53 svs. 36.97 ± 3.40 s,t=2.713), D-dimer (291.68 ± 25.15 mg/Lvs. 486.21 ± 44.32 mg/L,t=2.845), PLT (298.91×109/L ± 20.75×109/Lvs. 329.44×109/L ± 24.07×109/L,t=2.693) levels in TCM group significantly decreased (P<0.01).ConclusionHuoxue- Sanjie decoction combined with GEMOX chemotherapy regimen in the treatment of advanced pancreatic cancer for Shieryudu syndrome can improve the quality of life, prolong the survival time and helpreduce the risk of adverse events.